Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 06 - 16 tags : Disease save search
Tarsus Pharmaceuticals, Inc. Initiates Phase 1 Callisto Trial of TP-05, a Novel, Oral, Non-Vaccine Therapeutic for the Prevention of Lyme Disease
Published: 2021-06-16 (Crawled : 22:00) - biospace.com/
TARS | $32.77 -2.79% -2.87% 320K
|
Health Technology
|
| O: 0.23%
H: 1.5%
C: 0.71%
disease phase 1 vaccine trial phase 3 phase 2
Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer’s Disease
Published: 2021-06-16 (Crawled : 22:00) - biospace.com/
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: -0.45%
H: 2.21%
C: -0.76%
disease alzheimer phase 2 results topline antibody alzheimer’s alzheimer's disease alzheimer's
CNDAP Partners with Takeda to Develop New Therapies for Alzheimer's Disease and Related Brain Disorders
Published: 2021-06-16 (Crawled : 19:00) - prnewswire.com
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.29%
H: 0.0%
C: -0.53%
disease alzheimer therapy alzheimer’s alzheimer's disease alzheimer's train
Alzheimer's Disease Market Set To Witness Spells of Growth in the 7MM By 2030, Foresees DelveInsight
Published: 2021-06-16 (Crawled : 18:00) - prnewswire.com
DNLI | $15.55 -3.48% -3.6% 940K
|
Health Technology
|
| O: 0.16%
H: 1.21%
C: -0.12%
AVXL | $3.4 -7.61% -8.24% 2M
|
Health Technology
|
| O: 4.61%
H: 18.52%
C: 16.1%
disease alzheimer growth set alzheimer’s alzheimer's disease alzheimer's
Mirum Pharmaceuticals to Showcase Analyses From Its Rare Liver Disease Programs at The International Liver Congress 2021
Published: 2021-06-16 (Crawled : 16:00) - biospace.com/
MIRM | $24.0 -1.72% -1.75% 320K
|
Health Technology
|
| O: -0.22%
H: 2.67%
C: 0.28%
disease liver disease liver rare
Multi-Site Contributor Headlands Research Congratulates Biogen on FDA Approval of Aducanumab for Alzheimer’s Disease
Published: 2021-06-16 (Crawled : 15:15) - biospace.com/
KKR | $96.77 -1.23% 1.44% 3.6M
|
Finance
|
| O: 0.66%
H: 1.75%
C: 1.73%
disease alzheimer fda fda approval research approval alzheimer’s alzheimer's disease alzheimer's
DTx Pharma to Participate in the 2021 BMO BioPharma Day: Spotlight on Rare Disease and Ophthalmology
Published: 2021-06-16 (Crawled : 13:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.0%
H: 0.37%
C: -1.24%
disease biopharma rare pharma
Freeline Doses Second Patient of Phase 1/2 MARVEL-1 Clinical Trial for Fabry Disease
Published: 2021-06-16 (Crawled : 12:00) - biospace.com/
FRLN | $6.48 0.0% 0
|
Health Technology
|
| O: 4.52%
H: 0.0%
C: -4.93%
disease phase 1 trial phase 3 phase 2
Paratek Pharmaceuticals Announces Initiation of Phase 2b Study in Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus Complex (MABc) with NUZYRA® (omadacycline)
Published: 2021-06-16 (Crawled : 12:00) - globenewswire.com
PRTK | $2.23 0.0% 4.8M
|
Health Technology
|
| O: -1.47%
H: 0.84%
C: -10.81%
disease phase 2 phase 2b
CENTOGENE Reports First Quarter 2021 Financial Results in the Lead Up to Virtual Investor EventFurther signs of recovery in the core rare disease business
Published: 2021-06-16 (Crawled : 12:00) - biospace.com/
CNTG | $0.475 -1.04% -1.05% 19K
|
Commercial Services
|
| O: -0.69%
H: 2.48%
C: 0.69%
disease financial results results rare
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.